Phenytoin II: in vitro-in vivo bioequivalence standard for 100-mg phenytoin sodium capsules.
A bioequivalence study was undertaken using an oral solution, a fast-dissolving capsule and a slow-dissolving phenytoin sodium capsule. The AUC, tmax and Cmax correlated with in vitro dissolution data. The results of the present studies substantiate the presence of two types of phenytoin sodium products on the market. On the basis of these studies, in vitro specifications for fast- and slow-dissolving phenytoin sodium capsules as well as the in vivo bioequivalence requirements for these two types of products are recommended.
D002214:Capsules; D006801:Humans; D007700:Kinetics; D010672:Phenytoin / Q000008:administration & dosage* / Q000378:metabolism; D012995:Solubility; D013810:Therapeutic Equivalency
D002214:Capsules; D010672:Phenytoin